Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA, Set to Participate in Project Orbis BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)…
Zai Lab to Present Updated Phase 1 Data on DLL3-Targeted ADC Zocilurtatug Pelitecan (ZL-1310) at the 2025 AACR-NCI-EORTC International Conference Zai Lab Limited announced that new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly…
AskBio Reports Interim Safety Data from Phase 1/2 LION-CS101 Trial of AB-1003 in Limb-Girdle Muscular Dystrophy 2I/R9 AskBio Inc. (AskBio), a gene therapy company wholly owned by Bayer AG and operated independently, today announced that it will present initial safety…
Satellos Bioscience Reports Promising Safety, Tolerability, and Functional Benefits of SAT-3247 in Adults with Duchenne Muscular Dystrophy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on developing transformative therapies for degenerative muscle diseases, has unveiled new…
Vividion Publishes Groundbreaking Science Study on Covalent RAS-PI3Kα Inhibitors That Halt Tumor Growth Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and wholly owned, independently operated subsidiary of Bayer AG, has announced the publication of a pivotal manuscript in Science…
Charles River and Toxys Partner to Advance NAM-Based Developmental Toxicity Testing Through ReproTracker® Collaboration Charles River Laboratories International, Inc. (NYSE: CRL) and Dutch biotechnology company Toxys have announced a strategic collaboration that aims to reshape the landscape of developmental and…
RIBOMIC’s Umedaptanib Pegol Achieves Strong Growth Outcomes in Children with Achondroplasia: Phase 2 Data Support Advancement to Late-Stage Clinical Development RIBOMIC, Inc. (TOKYO: 4591), a Japan-based clinical-stage biotechnology company focused on aptamer therapeutics, announced highly encouraging results from its Phase…
DemeRx Secures $1.7 Million NIH Grant to Advance First-in-Class Neuroplastogen DMX-1001 for Alcohol Use Disorder DemeRx, Inc., a clinical-stage biopharmaceutical company committed to transforming addiction therapeutics through innovative neuroscience, announced that it has been awarded a $1.7 million Small Business…
KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies for hereditary angioedema (HAE) and related disorders, today unveiled compelling…
Merck Reports Clinical Positive Phase 3 HYPERION Trial Results for WINREVAIR™ (sotatercept-csrk) in Newly Diagnosed Pulmonary Arterial Hypertension Patients Merck known as MSD outside the United States and Canada, today announced encouraging findings from the Phase 3 HYPERION trial evaluating…
Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative therapies for life-threatening diseases, has announced the publication of Phase…